Neuroscience letters · 2025
Ferulic acid methylester improves the comorbidity of insomnia and anxiety in a rat model of PCPA-induced sleep disorder by activating DRN 5-HT neurons.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Quntao, Zhai Jingwen, Du Tongyu, He Junjie, Zhang Jingbin, Tian Yuhe, Ma Ketao, Si Junqiang, Yin Jiangwen, Li Yan
Аннотация
OBJECTIVE: Previous studies have indicated that ferulic acid possesses sedative and hypnotic functions. As a derivative of ferulic acid, ferulic acid methylester (FAM) exhibits stronger activity and lower toxicity than ferulic acid. This study is intended to establish a rat model of insomnia induced by PCPA, with the aim of exploring the improvement effect of FAM on the comorbidity of anxiety and insomnia in PCPA-induced insomnia model rats and its underlying mechanisms.
METHODS: Insomnia models were established by intraperitoneal injection of 400 mg/kg p-chlorophenylalanine (PCPA) in SD rats. FAM was administered at three doses: 10, 20, and 40 mg/kg. Anxiety levels were assessed using the elevated plus maze and open field tests. Sleep status was evaluated through 24-hour in vivo EEG monitoring. Immunofluorescence staining was used to observe changes in DRN 5-HT neuron activity. Chemogenetic techniques were employed to inhibit DRN 5-HT neurons to elucidate the underlying mechanism.
RESULTS: Behavioral tests revealed that FAM at 20 mg/kg significantly reduced anxiety levels (P < 0.001) and increased total sleep time (P < 0.001). EEG recordings showed improved sleep structure, with increased NREM and REM sleep times. Immunofluorescence staining indicated increased activity of DRN 5-HT neurons following FAM treatment. Chemogenetic inhibition of DRN 5-HT neurons reversed the beneficial effects of FAM on anxiety and sleep, thereby confirming the involvement of these neurons in the mechanism of action of FAM.
CONCLUSIONS: Ferulic acid methylester improves comorbidity of anxiety and insomnia in PCPA-induced insomnia model rats by activating DRN 5-HT neurons.
METHODS: Insomnia models were established by intraperitoneal injection of 400 mg/kg p-chlorophenylalanine (PCPA) in SD rats. FAM was administered at three doses: 10, 20, and 40 mg/kg. Anxiety levels were assessed using the elevated plus maze and open field tests. Sleep status was evaluated through 24-hour in vivo EEG monitoring. Immunofluorescence staining was used to observe changes in DRN 5-HT neuron activity. Chemogenetic techniques were employed to inhibit DRN 5-HT neurons to elucidate the underlying mechanism.
RESULTS: Behavioral tests revealed that FAM at 20 mg/kg significantly reduced anxiety levels (P < 0.001) and increased total sleep time (P < 0.001). EEG recordings showed improved sleep structure, with increased NREM and REM sleep times. Immunofluorescence staining indicated increased activity of DRN 5-HT neurons following FAM treatment. Chemogenetic inhibition of DRN 5-HT neurons reversed the beneficial effects of FAM on anxiety and sleep, thereby confirming the involvement of these neurons in the mechanism of action of FAM.
CONCLUSIONS: Ferulic acid methylester improves comorbidity of anxiety and insomnia in PCPA-induced insomnia model rats by activating DRN 5-HT neurons.